Gilead Sciences, Inc. (NASDAQ: GILD) is one of the. The company announced that the US FDA approved Yeztugo ® (lenacapavir), ...

New research analyzing an online survey of 1,633 respondents found a 15% recent use of doxycycline post- and pre‐exposure ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

"Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention" was originally created and published by ...

Increased PrEP usage is linked to decreased HIV diagnosis rates, with a notable decline from 13.0 to 10.6 per 100,000 over a decade. State-level PrEP coverage significantly impacts HIV diagnosis rates ...

HIV prevention pills are no different. The good news is PrEP (pre-exposure prophylaxis) is extremely effective and generally ...

Winning Founding Managing Editor and Executive Director of Cns (Citizen News Service) and Is a Feminist, Health and Development Justice Advocate.

The US Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV.

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis ...